Achondroplasia Treatment Market| Coherent Market Insights

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
ACHONDROPLASIA TREATMENT MARKET ANALYSIS

• Achondroplasia Treatment Market, By Drug
  Class (Lipase Inhibitor, Human Growth Hormone And
  Appetite Suppressants), By Distribution Channel
  (Hospitals Pharmacies, Speciality Clinics, Online
  Pharmacy, And Retail Pharmacy), By Patient Type
  (Adult And Paediatric), And By Region (North
  America, Latin America, Europe, Asia Pacific,
  Middle East, And Africa) - Size, Share, Outlook,
  and Opportunity Analysis, 2020 - 2027

3

• Market Drivers
• Achondroplasia is a rare disease which can be
  treated in various ways such as surgical
  treatment, hormone therapy, ongoing health care
  and limb lengthening. Therefore, pharmaceutical
  companies are focusing on product development in
  treatment of achondroplasia. For instance, in
  July 2020, BioMarin Pharmaceutical Inc. submitted
  a marketing authorization application to the
  European Medical Agency for vosoritide, an
  injection of c-type natriuretic peptide for
  treatment of achondroplasia. These factors are
  expected to drive growth of the global
  achondroplasia treatment market. Furthermore,
  pharmaceutical companies are focusing on research
  and development of treatments for achondroplasia.
  For instance, in June 2020, Biomarin
  Pharmaceuticals entered phase II clinical trials
  of evaluating safety, tolerability and efficacy
  of BMN III (Vosoritide)  in treating children
  with achondroplasia.

4
Global Achondroplasia Treatment Market COVID-19
Impact Analysis

• Since the outbreak of the COVID-19 pandemic,
  several markets across the globe have been
  affected negatively. Pharmaceutical companies
  operating in this market are facing challenges in
  carrying out clinical trials due to concerns
  regarding safety and wellbeing of participants.
  Furthermore, safety precautions which have been
  imposed to curb spread of the COVID-19 infection
  have created complications in carrying out
  surgical treatments and hormone therapy for
  achondroplasia.

5

• Market Restraints
• Cost of the growth hormone therapy ranges from
  US 10,000 to US 60,000 depending upon the
  amount of hormone used for the treatment
  therefore, growth hormone therapy is expensive
  for individuals in low- and mid-income countries.
  Moreover, growth hormone therapy is characterised
  by side effects such as carpal tunnel syndrome,
  higher insulin resistance and heightened risk of
  developing cancer. These factors are expected to
  restrain global achondroplasia treatment market
  growth.

6

• Market Regional Analysis
• . On the basis of regions, the global
  achondroplasia treatment market is segmented into
  North America, Latin America, Europe, Asia
  Pacific, Middle East, and Africa. According to
  National Library of Medicine 2018 report,
  prevalence of achondroplasia in North America is
  0.3 to 0.6 out of 10,000 individuals. Moreover,
  North America has various social associations
  such as Association of Little People of Alberto
  (ALPA) and Dwarf Athletic Association of Canada
  (DAAC) which offer health support and emotional
  support to patients with achondroplasia.
  Furthermore, pharmaceutical companies are
  focusing on strategies such mergers and
  acquisitions to innovate potential treatments for
  achondroplasia.

7
Market Regional Analysis

• In Europe, prevalence of achondroplasia is
  significantly more than other regions. According
  to the European Commission, in 2019, prevalence
  of achondroplasia was 3.67 per 10,000 births in
  the region. Therefore, pharmaceutical companies
  are focusing on research and development of
  treatments for achondroplasia to strengthen their
  share in the global anchondroplasia treatment
  market. For instance, in August 2020, Acendic
  Pharma A/S, a pharmaceutical company, received an
  orphan drug designation for Transcon, a c-type
  natriuretic peptide for treatment of
  achondroplasia from the European Commission.

8

• Key Players
• Key operating players in global achondroplasia
  treatment market are Ascendis Pharma A/S,
  BridgeBio Pharma, Inc., QED Therapeutics,
  BioMarin Pharmaceutical Inc., Pfizer Inc.,
  Therachon Holding AG and RIBOMIC Inc.
• Market Taxonomy
• On the basis of drug class, the global
  achondroplasia treatment market is segmented
  into
• Lipase Inhibitor
• Appetite Suppresants
• Human Growth Hormone

9
Key Players

• On the basis of distribution channel, the global
  achondroplasia treatment market is segmented
  into
• Hospital Pharmacies
• Online Pharmacy
• Retail Pharmacy
• On the basis of patient type, the global
  achondroplasia treatment market is segmented
  into
• Adult
• Paediatric

10
Key Players

• On the basis of region, the global achondroplasia
  treatment market is segmented into
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

11

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Referencehttps//www.coherentmarketinsights.com/o
  ngoing-insight/achondroplasia-treatment-market-416
  1

12
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

13
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

14

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/